NASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis $284.47 -4.78 (-1.65%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$286.55 +2.08 (+0.73%) As of 09/11/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ligand Pharmaceuticals Stock (NASDAQ:LGND) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ligand Pharmaceuticals alerts:Sign Up Key Stats Today's Range$283.77▼$294.0050-Day Range$280.18▼$322.6152-Week Range$161.82▼$326.63Volume261,161 shsAverage Volume176,224 shsMarket Capitalization$5.67 billionP/E Ratio30.42Dividend YieldN/APrice Target$335.75Consensus RatingBuy Company Overview Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that develops, acquires and licenses technologies designed to help pharmaceutical companies discover, develop and commercialize medicines. Rather than focusing primarily on building a large portfolio of internally marketed drugs, Ligand operates an asset-light business model centered on partnerships, licensing agreements, royalties and other economic interests in partnered products. The company’s principal technology is Captisol, a proprietary modified cyclodextrin designed to improve the solubility, stability and delivery of certain drug compounds. Captisol has been incorporated into a number of pharmaceutical products, including Kyprolis and Evomela. Ligand also has historically supported drug discovery and development through antibody and protein-expression technologies and provides capital or other resources to selected biotechnology partners in exchange for licensing rights, royalties or milestone payments. Founded in 1987 and headquartered in San Diego, California, Ligand formerly pursued a more traditional pharmaceutical research and development strategy before shifting toward its current partnership-focused model. Its technologies and royalty interests support medicines developed and sold by pharmaceutical companies in the United States and international markets, allowing Ligand to participate in commercial products without directly managing large-scale global sales operations.AI Generated. May Contain Errors. Read More Ligand Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreLGND MarketRank™: Ligand Pharmaceuticals scored higher than 79% of companies evaluated by MarketBeat, and ranked 135th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingBuy Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 9 buy ratings, no hold ratings, and no sell ratings.Upside PotentialLigand Pharmaceuticals has a consensus price target of $335.75, representing about 18.0% upside from its current price of $284.47.Amount of Analyst CoverageLigand Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ligand Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth56.52% Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 56.52% in the coming year, from $5.29 to $8.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 30.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.15.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 30.42, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.10.Price to Earnings Growth RatioLigand Pharmaceuticals has a PEG Ratio of 2.32. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 5.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ligand Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.18% of the float of Ligand Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 14.12, which indicates bearish sentiment.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently increased by 1.34%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.28 News SentimentLigand Pharmaceuticals has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Ligand Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for LGND on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,969,081.00 in company stock.Percentage Held by Insiders5.60% of the stock of Ligand Pharmaceuticals is held by insiders.Percentage Held by Institutions91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ligand Pharmaceuticals' insider trading history. Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LGND Stock News HeadlinesLigand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 SharesSeptember 9 at 4:21 AM | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Rating of "Buy" from BrokeragesSeptember 3, 2026 | americanbankingnews.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.September 12 at 1:00 AM | Awesomely (Ad)Ligand to Participate in September Investor ConferencesAugust 26, 2026 | globenewswire.comCraig-Hallum Keeps Their Buy Rating on Ligand Pharma (LGND)August 20, 2026 | theglobeandmail.comLigand Pharma (LGND) Gets a Buy from OppenheimerAugust 20, 2026 | theglobeandmail.comLigand Pharmaceuticals Earnings Call Signals Royalty-Driven SurgeAugust 17, 2026 | tipranks.comJason Haas Sells 7,138 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) StockAugust 15, 2026 | insidertrades.comSee More Headlines LGND Stock Analysis - Frequently Asked Questions How have LGND shares performed this year? Ligand Pharmaceuticals' stock was trading at $189.07 at the beginning of 2026. Since then, LGND shares have increased by 50.5% and is now trading at $284.47. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported $2.37 EPS for the quarter, topping the consensus estimate of $1.97 by $0.40. Ligand Pharmaceuticals's revenue was up 33.8% on a year-over-year basis. Read the conference call transcript. Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' top institutional shareholders include California State Teachers Retirement System (34.96%), Ranger Investment Management L.P. (1.29%), Bank of New York Mellon Corp (0.65%) and Squarepoint Ops LLC (0.11%). Insiders that own company stock include Todd C Davis, Matthew E Korenberg, John W Kozarich, Andrew Reardon, Stephen L Sabba, Octavio Espinoza, John L Lamattina, Nancy Ryan Gray and Jason Haas. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ligand Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/06/2026Today9/12/2026Next Earnings (Estimated)11/05/2026Investor Day 202612/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 LGND's financial health is in the Green zone, according to TradeSmith. LGND has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LGND CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees47Year Founded1987Price Target and Rating Average Price Target for Ligand Pharmaceuticals$335.75 High Price Target$388.00 Low Price Target$220.00 Potential Upside/Downside+18.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$9.35 Trailing P/E Ratio30.42 Forward P/E Ratio53.78 P/E Growth2.32Net Income$124.45 million Net Margins67.88% Pretax Margin81.90% Return on Equity20.06% Return on Assets11.68% Debt Debt-to-Equity Ratio1.16 Current Ratio31.18 Quick Ratio30.96 Sales & Book Value Annual Sales$290.54 million Price / Sales19.52 Cash Flow$7.72 per share Price / Cash Flow36.84 Book Value$51.68 per share Price / Book5.50Miscellaneous Outstanding Shares19,936,000Free Float18,820,000Market Cap$5.67 billion OptionableOptionable Beta1.11 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:LGND) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...Decentralized Masters | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...Investors Alley | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored17 Nobel Prize winners… one startling warningOn July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Three under-the-radar companies are already building the infrastructure behind a 200 billion government-backed...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
